New drug agent knocks out multiple enzymes in cancer pathway

March 25, 2009
New drug agent knocks out multiple enzymes in cancer pathway

University of Illinois chemistry department research scientist Yonghui Zhang (left), chemist Rong Cao (center), chemistry professor Eric Oldfield and their colleagues engineered a new bisphosphonate drug that is about 200 times more effective at killing cancer cells than a bisphosphonate drug used in a recent clinical trial. Credit: Photo by L. Brian Stauffer, U. of I. News Bureau.

A team of 24 researchers from the U.S., Europe, Taiwan and Japan and led by University of Illinois scientists has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.

The study appears this week in the .

The new agent belongs to a class of drugs called . These compounds were originally developed to treat osteoporosis and other bone diseases, but were recently found to also have potent anti-cancer and immune boosting properties.

Drug developers have tried for years to design drugs to inhibit pathways in , focusing on a protein called Ras since nearly a third of all human cancers involve a mutation in the Ras gene that causes cell signaling to go awry. These efforts have met with limited success.

Bisphosphonates act on other enzymes, called FPPS and GGPPS, which are upstream of Ras in the cell survival pathway. Inhibiting these enzymes appears to be a more effective strategy for killing cells.

When used in combination with hormone therapy in a recent clinical trial, the bisphosphonate drug zoledronate significantly reduced the recurrence of in premenopausal women with estrogen-receptor-positive breast cancer. Similar results were reported previously for hormone-refractory prostate cancer.

But zoledronate quickly binds to bone, reducing its efficacy in other tissues.

"We're trying to develop bisphosphonates that will be very active but won't bind to the bone, because if they bind to the bone they're not going to go to breast, lung or other tissues," said University of Illinois chemistry professor Eric Oldfield, who led the new study.

Oldfield's team also wanted to design a compound that would inhibit multiple enzymes in the tumor cell survival pathway, rather than just one, an approach analogous to the use of multi-kinase inhibitors in cancer therapy.

Andrew Wang, of Academia Sinica, Taipei, and Illinois chemist Rong Cao began by producing crystallographic structures of the target enzymes and drug candidates, allowing the researchers to identify those features that would enhance the drugs' ability to bind to the enzymes. Using this and other chemical data, Illinois chemistry department research scientist Yonghui Zhang engineered new bisphosphonate compounds that bound tightly to multiple enzyme targets, but not to bone.

One of the new compounds, called BPH-715, proved to be especially potent in cell culture and effectively inhibited tumor cell growth and invasiveness.

Tadahiko Kubo, of Hiroshima University, then found that BPH-715 also killed tumor cells in mice. And Socrates Papapoulos, of Leiden University, the Netherlands, showed that the compound had a very low chemical affinity for bone.

In humans, compounds like BPH-715 and zoledronate have an added benefit in fighting cancer: They spur the proliferation of immune cells called gamma delta T-cells, which aid in killing tumor cells.

"The new drugs are about 200 times more effective than the drugs used in recent clinical trials at killing tumor cells and in activating gamma delta T-cells to kill tumor cells," Oldfield said. "They also prevent tumor progression in mice much better than do existing bisphosphonate molecules."

Source: University of Illinois at Urbana-Champaign (news : web)

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

E_L_Earnhardt
Mar 25, 2009

Rank: not rated yet
Still "hung up" on treating a mal-functioning cell as a "VIRUS" That must be killed! A real good computer programmer, working on exact infa-red frequencies can restore the cell to health! Get off
the poisen thing!
Rank 5 /5 (2 votes)
Relevant PhysicsForums posts
  • Is Everyday Technology Killing Us?
    createdFeb 08, 2012
  • Exercise and weight loss
    createdFeb 08, 2012
  • Why do we have head aches? Our brains can't feel anything.
    createdFeb 07, 2012
  • "The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
    createdFeb 04, 2012
  • Oncolytic adenovirus
    createdFeb 04, 2012
  • Nutrition label stuffs and diets
    createdFeb 02, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Complex wiring of the nervous system may rely on a just a handful of genes and proteins

Researchers at the Salk Institute have discovered a startling feature of early brain development that helps to explain how complex neuron wiring patterns are programmed using just a handful of critical genes. ...

Medicine & Health / Research

created 11 hours ago | popularity 4.9 / 5 (9) | comments 1 | with audio podcast

Team isolates nerve cells involved in storing long term memory and gene proteins associated with them

(Medical Xpress) -- A research team in Taiwan has succeeded in isolating two nerve cells in fruit fly brains that are believed to be the major players in allowing for the formation of long term memories. Furthermore, ...

Medicine & Health / Neuroscience

created 17 hours ago | popularity 5 / 5 (4) | comments 2 | with audio podcast report

Seeing colors in music, tasting flavors in shapes may happen in life's early months

Famed violinist Itzhak Perlman sees a deep forest green whenever he plays a B-flat on his Stradivarius' G string. The A on the E string is red.

Medicine & Health / Psychology & Psychiatry

created 18 hours ago | popularity 4.5 / 5 (2) | comments 2 | with audio podcast

Both maternal and paternal age linked to autism

Older maternal and paternal age are jointly associated with having a child with autism, according to a recently published study led by researchers at The University of Texas Health Science Center at Houston (UTHealth).

Medicine & Health / Psychology & Psychiatry

created 15 hours ago | popularity 4.3 / 5 (3) | comments 0 | with audio podcast

New understanding of DNA repair could eventually lead to cancer therapy

A research group in the Faculty of Medicine & Dentistry at the University of Alberta is hoping its latest discovery could one day be used to develop new therapies that target certain types of cancers.

Medicine & Health / Cancer

created 14 hours ago | popularity 4.8 / 5 (6) | comments 0 | with audio podcast


Anonymous knocks CIA website offline (Update)

The website of the Central Intelligence Agency was inaccessible on Friday after the hacker group Anonymous claimed to have knocked it offline.

New error-correcting codes guarantee the fastest possible rate of data transmission

Error-correcting codes are one of the triumphs of the digital age. They’re a way of encoding information so that it can be transmitted across a communication channel — such as an optical fiber o ...

Google users warned of threat to smartphone wallets

Users of Google smartphone wallets were being warned on Friday that there is a way to crack pass codes intended to thwart thieves from going on illicit shopping sprees.

Humans may have helped the decline of African rainforests 3000 years ago

(PhysOrg.com) -- Large areas of rainforests in Central Africa mysteriously disappeared over three thousand years ago, to be replaced by savannas. The prevailing theory has been that the cause was a change ...

New power source discovered

(PhysOrg.com) -- Researchers at the Massachusetts Institute of Technology (MIT) and RMIT University have made a breakthrough in energy storage and power generation.

Small modular reactor design could be a 'SUPERSTAR'

(PhysOrg.com) -- Though most of today's nuclear reactors are cooled by water, we've long known that there are alternatives; in fact, the world's first nuclear-powered electricity in 1951 came from a reactor ...